Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Viking Therapeutics, Inc. (VKTX)
|
Add to portfolio |
|
|
|
| Price: |
$5.90
| | Metrics |
| OS: |
76.7
|
M
| |
-36
|
% ROE
|
| Market cap: |
$452
|
M
| |
-40
|
% ROIC
|
|
Net cash:
|
$169
|
M
| |
$2.20
|
per share
|
|
EV:
|
$284
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($59.8)
|
M
| |
|
|
|
EBIT
|
($59.8)
|
M
| |
|
|
| EPS |
($0.76)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Research and development | 45.0 | 31.9 | 23.6 | 19.0 | 13.7 | 9.0 | 7.0 | 22.2 |
| General and administrative | 10.7 | 10.7 | 9.1 | 7.1 | 5.3 | 4.8 | 5.0 | 1.2 |
| EBIT | -55.7 | -42.7 | -32.7 | -26.2 | -19.1 | -13.8 | -12.0 | -23.5 |
| Pre-tax income | -55.0 | -39.5 | -25.8 | -22.1 | -20.6 | -14.7 | -23.4 | -21.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -55.0 | -39.5 | -25.8 | -22.1 | -20.6 | -14.7 | -23.4 | -21.9 |
| |
| Diluted EPS | ($0.71) | ($0.54) | ($0.36) | ($0.38) | ($0.79) | ($0.90) | ($3.68) | ($5.23) |
| Shares outstanding (diluted) | 77.2 | 72.6 | 72.0 | 57.6 | 26.0 | 16.3 | 6.4 | 4.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|